Extremely Drug-Resistant Pseudomonas aeruginosa ST309 Harboring Tandem GES Enzymes: A Newly Emerging Threat in the United States
A. Khan, T. T. Tran, R. Rios, B. Hanson, W. C. Shropshire, Z. Sun, L. Diaz, A. Q. Dinh, A. Wanger, L. Ostrosky-Zeichner, T. Palzkill, C. A. Arias, W. R. Miller
The paper identifies two U.S. clinical isolates of Pseudomonas aeruginosa ST309 resistant to carbapenems and beta-lactam/beta-lactamase inhibitor combinations, harboring tandem GES 19 and 26 enzymes, and reports successful treatment with ceftazidime/avibactam plus aztreonam.
bioRxiv · Jan 30, 2019Microbiology